Description:
This inhaler is a triple combination therapy containing Glycopyrrolate, Formoterol, and Budesonide, used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and moderate to severe asthma. It provides a comprehensive approach by combining an anticholinergic, a long-acting bronchodilator, and an inhaled corticosteroid to offer enhanced bronchodilation, reduced inflammation, and improved respiratory function.
Components & Mechanism of Action:
Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that blocks the action of acetylcholine, preventing bronchoconstriction and reducing mucus secretion.
Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that relaxes airway smooth muscles, resulting in sustained bronchodilation and easier breathing.
Budesonide is an inhaled corticosteroid (ICS) that decreases airway inflammation by inhibiting the release of inflammatory mediators.
Therapeutic Uses:
Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Management of moderate to severe asthma in patients not adequately controlled with dual therapy
Reduction of respiratory symptoms such as wheezing, breathlessness, and chest tightness
Dosage Form:
Dry Powder Inhaler (DPI) or Metered-Dose Inhaler (MDI), depending on formulation
Prescription Status:
Prescription-only medication
Note:
This inhaler is for regular maintenance therapy and is not intended for acute symptom relief. A fast-acting reliever inhaler should be used for sudden respiratory distress. Patients should follow proper inhalation technique and rinse their mouth after use to minimize the risk of oral thrush. Always use under the guidance of a healthcare professional.
Would you like this version adapted for product brochures, online listings, or regulatory documents?
